Niknamian, 2020 - Google Patents
INTRODUCING COVID-19 AS AN EVOLUTIONARY METABOLIC INFECIOUS DISEASE (EMID) The Prime Cause and Representing Alternative Treatment for COVID …Niknamian, 2020
View PDF- Document ID
- 11177312192386637825
- Author
- Niknamian S
- Publication year
External Links
Snippet
Background: Coronaviruses are a group of related viruses that cause diseases in mammals and birds. In humans, coronaviruses cause respiratory tract infections that can range from mild to lethal. Mild illnesses include some cases of the common cold, while more lethal …
- 208000025721 COVID-19 0 title abstract description 51
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dube et al. | Repurposed drugs, molecular vaccines, immune‐modulators, and nanotherapeutics to treat and prevent COVID‐19 associated with SARS‐CoV‐2, a deadly nanovector | |
| Chen et al. | Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications | |
| Lucia et al. | Seebeck-like effect in SARS-CoV-2 bio-thermodynamics | |
| Law | COVID-19 pandemic: its origin, implications and treatments | |
| Siniavin et al. | Snake venom phospholipase A2s exhibit strong virucidal activity against SARS-CoV-2 and inhibit the viral spike glycoprotein interaction with ACE2 | |
| Niknamian | INTRODUCING COVID-19 AS AN EVOLUTIONARY METABOLIC INFECIOUS DISEASE (EMID) The Prime Cause and Representing Alternative Treatment for COVID-19 (SARS-CoV-2) | |
| Hanna et al. | Phototherapy as a rational antioxidant treatment modality in COVID-19 management; new concept and strategic approach: critical review | |
| Turpin et al. | Apoptosis during ZIKA virus infection: too soon or too late? | |
| Sahu et al. | SARS-CoV-2: phylogenetic origins, pathogenesis, modes of transmission, and the potential role of nanotechnology | |
| Aziz et al. | COVID-19 impacts, diagnosis and possible therapeutic techniques: a comprehensive review | |
| Molouki et al. | Newcastle disease virus infection promotes Bax redistribution to mitochondria and cell death in HeLa cells | |
| Tang et al. | Sophoridine suppresses herpes simplex virus type 1 infection by blocking the activation of cellular PI3K/Akt and p38 MAPK pathways | |
| Huang et al. | Mesenchymal stem cells and their derived small extracellular vesicles for COVID-19 treatment | |
| Sutter et al. | Manipulation of oxidative stress responses by non-thermal plasma to treat herpes simplex virus type 1 infection and disease | |
| Kaur et al. | A comprehensive review on epidemiology, aetiopathogenesis, diagnosis and treatment of the novel coronavirus syndrome–COVID-19 | |
| Nishimoto et al. | Transkingdom interactions important for the pathogenesis of human viruses | |
| Joseph et al. | State-of-the-art nanotechnology-based drug delivery strategies to combat covid-19 | |
| CN102256611B (en) | Anti-viral protection with viruses containing defective genome segments | |
| WO2015093957A2 (en) | Bacteria clearance with fogged bacteriophage. | |
| Bao et al. | Hydrophobic residues at the intracellular domain of the M2 protein play an important role in budding and membrane integrity of influenza virus | |
| Kumar | COVID-19 cure through stem cells | |
| Santa-Coloma | The airborne and gastrointestinal coronavirus SARS-COV-2 pathways | |
| Matsuzaka et al. | Extracellular Vesicle-Based SARS-CoV-2 Vaccine | |
| de Souza Cardoso et al. | Antiviral activity of dermaseptin 01 against Dengue virus type 2, Herpes simplex virus type 1 and Vaccinia virus [Abstract in English] | |
| CN115804775A (en) | Application of S63845 in preparation of anti-neocoronavirus infection medicine |